<DOC>
	<DOCNO>NCT02625324</DOCNO>
	<brief_summary>The purpose Valiant Evo International Clinical Trial demonstrate safety effectiveness Valiant Evo Thoracic Stent Graft System subject descend thoracic aortic aneurysm ( DTAA ) candidate endovascular repair . The Valiant Evo International Clinical Trial first-in human experience objective provide clinical data support CE mark via case series descriptive statistic .</brief_summary>
	<brief_title>Valiant Evo International Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Thoracic</mesh_term>
	<criteria>1 . Subject ≥18 year old 2 . Subject understand voluntarily sign date Patient Informed Consent approve Sponsor Ethics Committee study 3 . Subject present DTAA localize ostium leave subclavian artery ( LSA ) ostium celiac trunk 4 . Subject DTAA one following : 1 . A fusiform aneurysm maximum diameter : ≥ 50 mm and/or : ≥ 2 time diameter nonaneurysmal thoracic aorta and/or : &lt; 50 mm grow ≥ 5 mm within previous 12 month 2 . A saccular aneurysm penetrate atherosclerotic ulcer 5 . Subject 's anatomy must meet follow anatomical criterion demonstrate contrastenhanced CT and/or contrastenhanced MRI obtain within four ( 4 ) month prior implant procedure : 1 . Proximal distal nonaneurysmal aortic neck diameter measurement must ≥ 16 mm ≤ 42 mm 2 . Proximal nonaneurysmal aortic neck length must ≥ 20 mm ( FreeFlo configuration ) ≥ 25 mm ( Closed Web configuration ) 3 . Distal nonaneurysmal aortic neck length must ≥ 20 mm 6 . Subject adequate arterial access site tolerate conduit allow endovascular access aneurysmal site delivery system appropriate sized device choose treatment . 1 . Subject life expectancy le 1 year 2 . Subject participate another investigational drug device study would interfere endpoint followups study 3 . Subject pregnant 4 . Subject require plan placement cover proximal end stent graft occur zone 0 1 5 . Subject thoracic aneurysm contain rupture localize anastomosis previous graft ( pseudo/false aneurysm ) 6 . Subject mycotic aneurysm 7 . Subject dissection ( type A B ) intramural hematoma aortic rupture addition thoracic aneurysm 8 . Subject require emergent aneurysm treatment , e.g. , trauma rupture 9 . Subject receive previous stent stent graft previous surgical repair ascend and/or descend thoracic aorta , and/or aortic arch 10 . Subject require surgical endovascular treatment infrarenal aneurysm time implant 11 . Subject previous surgical endovascular treatment infrarenal aortic aneurysm 12 . Treatment Valiant Evo Thoracic Stent Graft would require intentional revascularization brachiocephalic artery , leave common carotid artery celiac trunk 13 . Subject plan major surgical interventional procedure within 30 day 30 day plan implantation Valiant Evo Thoracic Stent Graft . This include plan procedure need safe effective placement stent graft ( i.e. , carotid/subclavian transposition , carotid/subclavian bypass procedure ) 14 . Subject significant and/or circumferential aortic mural thrombus either proximal distal attachment site could compromise fixation seal implant stent graft 15 . Subject connective tissue disease ( e.g. , Marfan 's syndrome , aortic medial degeneration ) 16 . Subject bleed diathesis coagulopathy , refuse blood transfusion . 17 . Subject MI within 3 month procedure 18 . Subject CVA within 3 month procedure 19 . Subject know allergy intolerance device material 20 . Subject know allergy anesthetic drug 21 . Subject know hypersensitivity contraindication anticoagulant , contrast medium , amenable pretreatment 22 . Subject active systemic infection time index procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>